Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole as Adjunctive Therapy in MDD (Sirius)
NCT02196506Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jul 2014; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02196506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02196506.